Physician profile
Laken Meadows
NPI 1730841487
$1,765.33
in general payments reported to CMS, 2019-2025
28 companies · $417 in 2025
The $417 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $60.08 · 2022: $509 · 2023: $380 · 2024: $400 · 2025: $417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,196.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $307.91 | 2022-2025 | |
| Novo Nordisk INC | $265.89 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $143.42 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $137.22 | 2021-2025 | Airsupra, Farxiga |
| Astellas Pharma US INC | $130.56 | 2023-2025 | Veozah |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.88 | 2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.55 | 2022-2025 | Jardiance |
| Glaxosmithkline, LLC. | $87.60 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $76.12 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $66.38 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.25 | 2022-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $34.91 | 2024 | Voquezna |
| Dexcom, INC. | $34.69 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $26.65 | 2022 | |
| Phadia US INC. | $24.94 | 2024 | Immunocap |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $18.84 | 2023 | Rexulti |
| Pfizer INC. | $18.06 | 2025 | |
| Amarin Pharma, INC. | $17.14 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $16.15 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.54 | 2022 | |
| Kaleo, INC. | $15.40 | 2022 | |
| Xeris Pharmaceuticals, INC. | $15.24 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $15.02 | 2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
| Acella Pharmaceuticals, LLC | $14.95 | 2025 | NP Thyroid 60 |
| Redhill Biopharma INC. | $13.70 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.70 | 2022 | |
| Currax Pharmaceuticals LLC | $12.99 | 2023 | Contrave |
| Genentech USA, INC. | $2.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laken Meadows listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.